Grifols A : 2021 a year to forget: preview H2 2021
>Reducing estimates ahead of Grifols FY 2021 (H2 2021) results due on 28 February at market open - Ahead of the FY 2021 results, we have cut our estimates to consider: 1/ lower sales and margins than expected in H2 2021 due to the recent weak trend in plasma donations in the US; 2/ reduction of Griffols stake in Biotest AG from 100% to 70% as a result of the success of the public takeover offer (adjusting minorities and gross debt/cash/financials) whilst we are now co...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.